Latest Intelligence on Influenza

Published within

« | 1 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor
29 Jun 2010
Expert View
Expert View

BiondVax: new Phase II data heat up the race for the first universal influenza vaccine

New data presented at the World Vaccines Congress demonstrate that BiondVax's developmental influenza vaccine can also act as a booster to existing seasonal influenza vaccines in elderly patients. A vaccine with increased efficacy in the elderly is one of the largest unmet needs in influenza prevention, although the need for patients to take multiple vaccinations may hinder its success.

Published By Datamonitor
13 Apr 2012
CommentWire
CommentWire

Emergent Biosolutions: acquisition of FluBlok to strengthen infectious diseases portfolio

Emergent Biosolutions' agreement to buy the influenza vaccine FluBlok indicates a continued interest in expanding its infectious diseases portfolio, following acquisitions related to anthrax vaccination. This latest addition, once approved, will enable entry into the expanding influenza sector, which is predicted to reach total sales of almost $5 billion by 2016 across the seven major markets.

Published By Datamonitor
29 May 2008
CommentWire
CommentWire

GlaxoSmithKline: H1N1 hype unfounded as UK caps vaccine order

Following poor uptake of the vaccine in several European markets, the UK Department of Health has opted to limit its H1N1 contract with GlaxoSmithKline to 34.8 million doses. Despite the media hype surrounding the influenza outbreak, the mild course of the pandemic and negative public opinion of the vaccine means that its commercial impact will be significantly reduced.

Published By Datamonitor
08 Apr 2010
Expert View
Expert View

J&J/Crucell: influenza deal signals shifts in the wider flu market

Johnson & Johnson and Crucell have entered into an agreement to develop and commercialize Crucell's universal influenza antibodies for the treatment and prevention of influenza. The deal strengthens Johnson & Johnson's presence in infectious diseases and gives it its first foothold in vaccines. Moreover, the deal is indicative of healthcare firms' increasing interest in influenza vaccines.

Published By Datamonitor
01 Oct 2009
CommentWire
CommentWire

Novavax: competitors may follow lead in regional strategy

US biotech Novavax has initiated a pivotal two-stage study for its H1N1 influenza vaccine in Mexico. Novavax's strategy of pursuing approval for the vaccine in smaller markets before targeting the US represents an alternative and faster route to market. Given the many benefits of this strategy, Datamonitor believes that it may be adopted by other small vaccine companies in the future.

Published By Datamonitor
21 Oct 2009
Expert View
Expert View

Pandemic flu: gaps in preparedness remain

The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.

Published By Datamonitor
08 May 2009
CommentWire
CommentWire

Roche: Tamiflu sales hit by fading flu hype

Sales of Tamiflu, Roche's influenza treatment, have plummeted by 68% compared to 2007, reflecting the waning attention paid to pandemic preparation by governments worldwide and the emerging competition from Relenza and pandemic influenza vaccines. Despite insufficient stockpiles in most countries, Datamonitor believes that the seasonal market will continue to gain importance for Tamiflu's sales.

Published By Datamonitor
05 Feb 2009
Expert View
Expert View

Universal vaccines: despite advantages, doubts remain

The need for yearly updates and the low coverage of existing influenza vaccines has created an unmet need for products providing a wider and longer-lasting immunity. Several companies are therefore developing "universal" influenza vaccines that make annual vaccination unnecessary, mainly targeting the highly conserved M2e domain of the virus, although doubts regarding their real benefits remain.

Published By Datamonitor
23 Nov 2007

« | 1 | » »|

No help is available.